Lario Therapeutics Secures $6M Grant from Michael J. Fox Foundation for Parkinson’s Research Lario Therapeutics, a biopharmaceutical company focused on pioneering precision medicines for neurological and epileptic disorders, has announced it has been awarded a $6 million USD grant from…
Ionis Pharmaceuticals today revealed that it has finalized enrollment in its pivotal trial evaluating zilganersen (ION373), an investigational RNA-targeted therapy aimed at treating children and adults with Alexander disease (AxD), a rare, progressive, and ultimately fatal neurological disorder. The trial’s…
WHO and UNICEF have unveiled new national immunization coverage estimates (WUENIC), offering the most comprehensive view of global vaccination trends for 13 diseases. The findings present both progress and pressing challenges. In 2023, 108 million children worldwide received three doses…
Neurocrine Biosciences has introduced a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the leading VMAT2 inhibitor for treating adults with tardive dyskinesia and chorea associated with Huntington’s disease. This new INGREZZA® SPRINKLE (valbenazine) formulation is now available through the same…
A prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has once again been named a constituent of the FTSE4Good Index Series. This recognition, marking the fourth year in a row, highlights the company’s exceptional performance in sustainability. The FTSE4Good…
The Severe Acute Respiratory Infections Network (SARInet) is a regional collaboration comprising professionals from hospitals, laboratories, health organizations, and institutions across Member States of the Americas. SARInet, coordinated by the Pan American Health Organization/World Health Organization (PAHO/WHO), marked its 10th…
Country-level preparedness for influenza pandemics is crucial to mitigate global spread and its associated impacts on health and economies. Pandemics can cause widespread illness, high mortality rates, and substantial economic burdens due to healthcare costs and productivity losses. Through coordinated…
Genexine (KOSDAQ: 095700), a Korean clinical-stage biopharmaceutical firm dedicated to developing innovative biologics for critical medical needs, has announced a merger with EPD Biotherapeutics (referred to as ‘EPD Bio’), a pioneer in targeted protein degradation (TPD) bioPROTAC platform technology. This…
Owkin, the first end-to-end AI-biotech unicorn specializing in AI-driven precision drug discovery, development, and diagnostics, has announced its expansion into the DACH region (Germany, Austria, and Switzerland). This follows partnerships with nine top centers in the region, including Charité –…
Owkin, the pioneering AI-biotech unicorn specializing in AI-driven precision drug discovery, development, and diagnostics, has launched its expansion into the DACH region (Germany, Austria, and Switzerland). This expansion follows strategic partnerships with nine leading institutions in the region, including Charité…
Biogen, headquartered in Cambridge, Massachusetts, and led by CEO Christopher A. Viehbacher, announced today the launch of “LEQEMBI®” (known as “乐意保®” in China), a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, in China. Approved in January 2024 for treating mild…
Today, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of their Omicron JN.1-adapted monovalent COVID-19 vaccine, COMIRNATY® JN.1, for active immunization against COVID-19 caused…
